We are live on ! Find out more
SMMT icon

Summit Therapeutics
SMMT

93 hedge funds and large institutions have $60.4M invested in Summit Therapeutics in 2023 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 34 increasing their positions, 22 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,170% more call options, than puts

Call options by funds: $2.1M | Put options by funds: $165K

55% more repeat investments, than reductions

Existing positions increased: 34 | Existing positions reduced: 22

0.38% less ownership

Funds ownership: 5.01% → 4.63% (-0.38%)

7% less funds holding

Funds holding: 100 → 93 (-7)

31% less capital invested

Capital invested by funds: $87.7M → $60.4M (-$27.3M)

47% less first-time investments, than exits

New positions opened: 8 | Existing positions closed: 15

Holders
93
Holders Change
-7
Holders Change %
-7%
% of All Funds
1.48%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
8
Increased
34
Reduced
22
Closed
15
Calls
$2.1M
Puts
$165K
Net Calls
+$1.93M
Net Calls Change
+$1.99M

Top Buyers

Rank Fund Capital Flow
1
Charles Schwab
Charles Schwab
California
+$1.2M
2
Geode Capital Management
Geode Capital Management
Massachusetts
+$530K
3
BlackRock
BlackRock
New York
+$408K
4
Barclays
Barclays
United Kingdom
+$190K
5
JP Morgan Chase
JP Morgan Chase
New York
+$186K

Top Sellers

Rank Fund Capital Flow
1
BBA
Baker Bros. Advisors
New York
-$6.03M
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$482K
3
Group One Trading
Group One Trading
Illinois
-$350K
4
Goldman Sachs
Goldman Sachs
New York
-$303K
5
Millennium Management
Millennium Management
New York
-$293K
Name Holding Trade Value Shares
Change 		Change in
Stake
Citigroup
76
Citigroup
New York
$16.9K -$77.8K -40,786 -82%
Belvedere Trading
77
Belvedere Trading
Illinois
$16.8K -$5.51K -2,889 -24%
TRCT
78
Tower Research Capital (TRC)
New York
$12.6K +$3.54K +1,858 +38%
MLICM
79
Metropolitan Life Insurance Company (MetLife)
New York
$12.3K – – –
OCM
80
Osterweis Capital Management
California
$9.35K – – –
Fidelity Investments
81
Fidelity Investments
Massachusetts
$5.78K +$4.7K +2,464 +394%
Daiwa Securities Group
82
Daiwa Securities Group
Japan
$5K – – –
S
83
SignatureFD
Georgia
$4.88K +$4.17K +2,188 +518%
Russell Investments Group
84
Russell Investments Group
United Kingdom
$4.71K +$4.8K +2,517 New
ATC
85
Adirondack Trust Company
New York
$4.65K – – –
GWMIA
86
Global Wealth Management Investment Advisory
Florida
$3.74K – – –
LFG
87
Larson Financial Group
Missouri
$3.08K – – –
National Bank of Canada
88
National Bank of Canada
Quebec, Canada
$2.81K – – –
LC
89
Lindbrook Capital
California
$1.46K +$80 +42 +6%
BCPWM
90
Bradley & Co Private Wealth Management
Florida
$374 – – –
Nisa Investment Advisors
91
Nisa Investment Advisors
Missouri
$168 -$8 -4 -4%
AF
92
Allworth Financial
California
$120 +$122 +64 New
Millennium Management
93
Millennium Management
New York
– -$293K -116,723 Closed
VF
94
Virtu Financial
New York
– -$109K -43,563 Closed
CAPTRUST Financial Advisors
95
CAPTRUST Financial Advisors
North Carolina
– -$90.2K -35,926 Closed
Tudor Investment Corp
96
Tudor Investment Corp
Connecticut
– -$80.6K -32,103 Closed
ECM
97
ExodusPoint Capital Management
New York
– -$65K -25,775 Closed
EW
98
Evoke Wealth
California
– -$63.3K -25,218 Closed
Simplex Trading
99
Simplex Trading
Illinois
– -$47.9K -25,114 Closed
Jane Street
100
Jane Street
New York
– -$53.7K -21,399 Closed
1 2 3
4
5

SMMT Hedge Fund Activity: Q3 2023 in Review

93 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Summit Therapeutics (SMMT) for Q3 2023, worth a combined $60.4M — down 31% from $87.7M a quarter earlier.

Sellers outnumbered buyers: 15 funds closed out of SMMT and 8 opened new positions — a net loss of 7 holders — while 22 trimmed existing stakes and 34 added.

The largest buyer was Charles Schwab, adding an estimated $1.2M. The largest seller was Baker Bros. Advisors, cutting an estimated $6.03M.

  • 93 institutional investors held Summit Therapeutics (SMMT) as of Q3 2023, down from 100 in Q2 2023.
  • Funds reported $60.4M of Summit Therapeutics stock for Q3 2023, down 31% quarter-over-quarter.
  • 8 funds opened new Summit Therapeutics positions in Q3 2023 and 15 closed out, a net change of -7 holders.
  • The largest Summit Therapeutics buyer in Q3 2023 was Charles Schwab, an estimated $1.2M added.
  • The largest Summit Therapeutics seller in Q3 2023 was Baker Bros. Advisors, an estimated $6.03M sold.

Based on aggregated 13F filings for Q3 2023.